Exciting news: our website for the first and only oral on-demand #HAE treatment has earned a Silver Award for Branded Website for Consumers at the 2026 @MMMnews Awards. We’re proud to share this honor with the entire HAE community.
KalVista Pharmaceuticals, Inc.
Verified account This account is verified. Learn more@KalVista
Advancing novel medicines to empower the everyday lives of people living with hereditary angioedema (HAE).
64 Following 608 Followers 330 Posts
Latest posts 5
The #HAE community is gathering in Ottawa, and KalVista is here! Meet us at the 2026 HAEi Regional Conference Americas, October 23–25, hosted by @HAEDAY. Learn more about the conference: bit.ly/4z2hW1d
Long-term prophylaxis can help people manage #HAE—but it often does not eliminate attacks. Real-world data reinforce that on-demand treatment remains foundational to care, helping people stay prepared to treat whenever an attack occurs: bit.ly/4z7WDLz
KalVista is proud to be a 2026 @FiercePharma Fierce 50 Breakthrough Honoree—a recognition we share with the entire HAE community: bit.ly/4h8PrZo
Interim results from the KONFIDENT-S OLE have been published in JACI Global. The analysis evaluated the safety and efficacy of our oral on-demand treatment in people with #HAE receiving long-term prophylaxis: bit.ly/4xzD6CA
0:07